study effects of rosuvastatin on markers of atherosclerosis, thrombosis, in diabetic patients treated with glimepiride/metformin without coronary artery disease. This effect will be investigated especially on sortilin ,fetuin-A
A randomized controlled trial on 70 patients with DM type 2 will be recruited from Damanhour national medical institute. * Subjects will be divided into two group (one arm is DM-type 2 patients who will receive rosuvastatin -metformin-glimepiride combination (40 patients) and another arm is DM-type 2 patient who will receive glimepiride-metformin combination (30 patients). * Determination of serum levels of fetuin A and Sortilin * Blood samples will be collected after 3-month after active treatment. * Outcomes measurement : Sortilin ,fetuinA, Atherogenic index (AI) and coronary risk index (CRI) . Methodology * Sortilin, fetuinA will be determined by ELISA. * Lipid profile. * FBG and Hb A1C will be measured. * Atherogenic index (AI = LDL-C/HDL-C) and CRI (CRI = TC/HDL-C) will be calculated for all subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
70
Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
Damanhour Medical National Institute
Damanhūr, N/A = Not Appُlicable, Egypt
serum levels of fetuin A
Fetuin-A has a diagnostic potential as a biomarker for liver dysfunction, cardiovascular diseases and disorders associated with metabolic syndrome.
Time frame: three months
serum levels of Sortilin
Sortilin is involved in lipid metabolism, promotes the development of atherosclerosis, and possibly becomes a potential therapeutic target for atherosclerosis treatment.
Time frame: three months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.